Keyword: Yescarta (axicabtagene ciloleucel)
New CMS rules have removed some restrictions on healthcare providers that could in turn boost uptake of Gilead's and Novartis' CAR-T drugs.
Kite has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors but says it is time to produce its own.
At the ASCO meeting in Chicago, Gilead touted its important new franchise with analyses and data on approved and up-and-coming CAR-Ts.
Gilead tapped new CEO Daniel O’Day in part because of his cancer expertise. But he’s not planning to lead the company’s oncology ramp-up alone.
Gilead CFO Robin Washington plans to retire next March, giving brand-new CEO Daniel O'Day his first C-suite slot to fill.
With Yescarta on the market and other CAR-Ts on their way, Gilead’s Kite Pharma planted the flag for another manufacturing site.
With Ranexa and Letairis copies ready to bite $1.2 billion off its top line, Gilead's cutting loose 150 salespeople who rep its cardiopulmonary drugs.
French biotech Cellectis is building facilities in Paris and the U.S. to produce allogeneic CAR-T treatments.
Payer coverage is key to Novartis’ plan to get Kymriah going, and the company is going to be getting some more of that.
The cell and gene therapy fields remain in early stages, but Novartis' CEO sees a big future. He's working to position Novartis ahead of the pack.